Patients Treated With Alemtuzumab Clinical Trial
Official title:
Asian Multinational Retrospective Analysis for Infectious Complications in Patients Treated With Alemtuzumab
| Verified date | May 2012 |
| Source | Samsung Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Korea: Ministry for Health and Welfare |
| Study type | Observational |
The aim of this study is to propose infection prophylaxis from Asian multinational retrospective analysis of infectious complications in patients who were treated with alemtuzumab
| Status | Completed |
| Enrollment | 182 |
| Est. completion date | March 2012 |
| Est. primary completion date | March 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 15 Years to 90 Years |
| Eligibility |
Inclusion Criteria: - Patients received alemtuzumab as a treatment for hematologic malignancy ex. non-Hodgkin lymphoma Acute myeloid leukemia Aplastic anemia Exclusion Criteria: - Patients did not receive alemtuzumab |
Observational Model: Cohort, Time Perspective: Retrospective
| Country | Name | City | State |
|---|---|---|---|
| China | Queen Mary Hospital | Hong Kong | |
| Indonesia | Cipto Mangunkusumo General Hospital | Jakarta | |
| Korea, Republic of | Samsung Medical Center | Seoul | |
| Taiwan | National Taiwan University Hospital | Teipei | |
| Thailand | Chulalongkorn University | Bangkok |
| Lead Sponsor | Collaborator |
|---|---|
| Samsung Medical Center | Asan Medical Center, Chonbuk National University, Chonnam National University, Chulalongkorn University, Dr Cipto Mangunkusumo General Hospital, Kyungpook National University, National Taiwan University Hospital, Queen Mary Hospital, Hong Kong, Soon Chun Hyang University, Yonsei University |
China, Indonesia, Korea, Republic of, Taiwan, Thailand,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Infectious event | Any infectious complication occurred within one year after the use of alemtuzumab | one year | Yes |